STOP THE WAR! Let’s support Ukraine Together

MedTech Acquisition Corp (MTAC) to Combine with TriSalus Life Sciences in $234M Deal

MedTech Acquisition Corp (MTAC) to Combine with TriSalus Life Sciences in $234M Deal

MedTech Acquisition Corporation (NASDAQ:MTAC) has entered into a definitive agreement to combine with drug developer TriSalus Life Sciences at an enterprise value of $234 million. Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device. The combined company is expected to trade on the Nasdaq under the
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.